Want to see VCYT full AI Analyst Report?
VCYT Stock Chart & Stats
$44.04
-$1.27(-2.19%)
At close: 4:00 PM EDT
$44.04
-$1.27(-2.19%)
Day’s Range― - ―
52-Week Range$29.46 - $60.91
Previous Close$55.6
Volume589.88K
Average Volume (3M)1.40M
Market Cap
$3.72B
Enterprise Value$4.37B
Total Cash (Recent Filing)$485.23M
Total Debt (Recent Filing)$40.11M
Price to Earnings (P/E)32.1
Beta0.97
Next Earnings
Nov 04, 2026EPS Estimate
0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.44
Shares Outstanding80,390,730
10 Day Avg. Volume1,199,749
30 Day Avg. Volume1,402,933
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)2.53
Price to Sales (P/S)6.40
P/FCF Ratio26.13
Enterprise Value/Market Cap1.18
Enterprise Value/Revenue7.78
Enterprise Value/Gross Profit10.80
Enterprise Value/Ebitda33.71
Forecast
1Y Price Target
$58.50Price Target Upside32.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)1.91
Revenue Forecast (FY)$593.71M
Bulls Say, Bears Say
Bulls Say
Profitability And Revenue GrowthVeracyte has moved from substantial historical losses to stronger profitability while continuing to grow revenue. Improving margins indicate operating leverage and a more scalable diagnostics model, supporting the company’s ability to fund product development and strengthen earnings over the next several quarters.
Cash Generation And Low LeverageRobust operating and free cash flow, combined with very low debt, gives Veracyte meaningful financial flexibility. Cash generation that closely tracks earnings can support clinical evidence, commercialization, technology investment, and acquisitions without creating material balance-sheet strain.
Expanding Diagnostic PortfolioExpansion into breast cancer and bladder cancer broadens Veracyte beyond its established Afirma and Decipher franchises. These products add new clinical use cases and increase the company’s opportunity to provide genomic insights across multiple points in the cancer-care pathway.
Bears Say
Prosigna Reimbursement UncertaintyProsigna’s commercial contribution remains dependent on completing the reimbursement and pricing process for the centralized LDT. Until that is resolved, adoption may not translate into expected revenue, making the launch’s contribution to medium-term growth less certain.
Low-Risk Decipher Evidence RiskThe revised NCCN guidance has already reduced expected low-risk Decipher volume and may limit physician utilization in that segment. Additional evidence is underway, but its outcome is uncertain, creating a durable risk to adoption and growth in an important use case.
Early TrueMRD CommercializationTrueMRD expands Veracyte’s addressable market, but its commercial impact is not yet established. The company still needs to develop additional assays, generate supporting evidence, and execute further launches, so near- to medium-term returns from this platform remain uncertain.
Veracyte News
VCYT FAQ
What was Veracyte’s price range in the past 12 months?
Veracyte lowest stock price was $29.45 and its highest was $60.91 in the past 12 months.
What is Veracyte’s market cap?
Veracyte’s market cap is $3.72B.
When is Veracyte’s upcoming earnings report date?
Veracyte’s upcoming earnings report date is Nov 04, 2026 which is in 13 days.
How were Veracyte’s earnings last quarter?
Veracyte released its earnings results on Jul 30, 2026. The company reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.13.
Is Veracyte overvalued?
According to Wall Street analysts Veracyte’s price is currently Undervalued.
Does Veracyte pay dividends?
Veracyte does not currently pay dividends.
What is Veracyte’s EPS estimate?
Veracyte’s EPS estimate is 0.41.
How many shares outstanding does Veracyte have?
Veracyte has 80,390,730 shares outstanding.
What happened to Veracyte’s price movement after its last earnings report?
Veracyte reported an EPS of $0.54 in its last earnings report, beating expectations of $0.41. Following the earnings report the stock price went down -22.516%.
Which hedge fund is a major shareholder of Veracyte?
Currently, no hedge funds are holding shares in VCYT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Veracyte Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$58.50 (32.83% Upside)
$58.50 (32.83% Upside)
Blogger Sentiment
Bullish
VCYT Sentiment 78%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 464.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 9.3%
Last 30 Days ▲ 9.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
28.03%
12-Months-Change
Fundamentals
Return on Equity
8.64%
Trailing 12-Months
Asset Growth
10.58%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Veracyte
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
VCYT Company Deck
VCYT Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was strongly positive, characterized by 15% total revenue growth, 19% testing revenue growth, improved profitability and cash generation, raised full-year revenue guidance, successful launches of Prosigna LDT and TrueMRD, and continued momentum in Decipher and Afirma. The primary challenges were concentrated in the low-risk Decipher segment, pending Prosigna LDT reimbursement and workflow integration, early TrueMRD commercialization, and tougher Afirma comparisons expected next year.View all VCYT earnings summariesVCYT Stock 12 Month Forecast
Average Price Target
$58.50
▲(32.83% Upside)
Technical Analysis
Ownership Overview
1.71% Insiders
34.08% Mutual Funds
3.46% Other Institutional Investors
20.22% Public Companies and
Individual Investors